PTC Therapeutics
PTCT
261 hedge funds and large institutions have $4.02B invested in PTC Therapeutics in 2025 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 85 increasing their positions, 94 reducing their positions, and 27 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
85% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 27
27% more call options, than puts
Call options by funds: $15.8M | Put options by funds: $12.5M
15% more capital invested
Capital invested by funds: $3.51B → $4.02B (+$516M)
9% more funds holding
Funds holding: 240 → 261 (+21)
0.9% less ownership
Funds ownership: 100.76% → 99.87% (-0.9%)
10% less repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 94
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$59.6M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$37M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$35.4M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$31.5M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$29.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$84.8M |
| 2 |
Blackstone Inc
New York
|
-$47.8M |
| 3 |
AC
Armistice Capital
New York
|
-$47.1M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$39.4M |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$33.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
I
276
InceptionR
Lafayette,
California
| – | -$321K | -7,115 | Closed |
|
277
Ohio Public Employees Retirement System (OPERS)
Columbus,
Ohio
| – | -$250K | -5,542 | Closed |
|
|
SC
278
Savant Capital
Rockford,
Illinois
| – | -$210K | -4,648 | Closed |
|
|
RS
279
R Squared
Central,
Hong Kong
| – | -$79K | -1,750 | Closed |
|
|
VWM
280
Venturi Wealth Management
Austin,
Texas
| – | -$67.7K | -1,500 | Closed |
|
|
PD
281
Point72 (DIFC)
Dubai,
United Arab Emirates
| – | -$37.7K | -835 | Closed |
|
|
CAS
282
Coppell Advisory Solutions
Coppell,
Texas
| – | -$24.4K | -533 | Closed |
|
|
SAM
283
Synergy Asset Management
Vancouver,
Washington
| – | -$15.6K | -420 | Closed |
|
|
AAP
284
Arax Advisory Partners
Denver,
Colorado
| – | -$4.7K | -104 | Closed |
|
|
ACM
285
Aster Capital Management
Dubai,
United Arab Emirates
| – | -$4.42K | -98 | Closed |
|
|
LSA
286
Leonteq Securities AG
Zurich,
Switzerland
| – | -$3.97K | -88 | Closed |
|
|
EC
287
Elequin Capital
New York
| – | -$90 | -2 | Closed |
|
PTCT Hedge Fund Activity: Q1 2025 in Review
261 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q1 2025, worth a combined $4.02B — up 15% from $3.51B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new PTCT positions and 27 closed out — a net gain of 23 holders — while 85 added to existing stakes and 94 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $59.6M. The largest seller was Camber Capital Management, cutting an estimated $84.8M.
- 261 institutional investors held PTC Therapeutics (PTCT) as of Q1 2025, up from 240 in Q4 2024.
- Funds reported $4.02B of PTC Therapeutics stock for Q1 2025, up 15% quarter-over-quarter.
- 50 funds opened new PTC Therapeutics positions in Q1 2025 and 27 closed out, a net change of +23 holders.
- The largest PTC Therapeutics buyer in Q1 2025 was Fidelity Investments, an estimated $59.6M added.
- The largest PTC Therapeutics seller in Q1 2025 was Camber Capital Management, an estimated $84.8M sold.
Based on aggregated 13F filings for Q1 2025.